ATE299509T1 - Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen - Google Patents

Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Info

Publication number
ATE299509T1
ATE299509T1 AT02076058T AT02076058T ATE299509T1 AT E299509 T1 ATE299509 T1 AT E299509T1 AT 02076058 T AT02076058 T AT 02076058T AT 02076058 T AT02076058 T AT 02076058T AT E299509 T1 ATE299509 T1 AT E299509T1
Authority
AT
Austria
Prior art keywords
phosphoramidites
new
production
alkyl
alkyl nucleosides
Prior art date
Application number
AT02076058T
Other languages
English (en)
Inventor
Daniel Peter Claude Mcgee
Phillip Dan Cook
Charles John Guinosso
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/918,362 external-priority patent/US5506351A/en
Priority claimed from US07/967,267 external-priority patent/US7101993B1/en
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE299509T1 publication Critical patent/ATE299509T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02076058T 1992-07-23 1993-07-20 Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen ATE299509T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/918,362 US5506351A (en) 1992-07-23 1992-07-23 Process for the preparation of 2'-O-alkyl guanosine and related compounds
US07/967,267 US7101993B1 (en) 1990-01-11 1992-10-27 Oligonucleotides containing 2′-O-modified purines
US96884992A 1992-10-30 1992-10-30

Publications (1)

Publication Number Publication Date
ATE299509T1 true ATE299509T1 (de) 2005-07-15

Family

ID=27420643

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02076058T ATE299509T1 (de) 1992-07-23 1993-07-20 Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
AT93917287T ATE256143T1 (de) 1992-07-23 1993-07-20 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93917287T ATE256143T1 (de) 1992-07-23 1993-07-20 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Country Status (7)

Country Link
EP (2) EP1223173B1 (de)
JP (3) JP3015464B2 (de)
AT (2) ATE299509T1 (de)
AU (1) AU4684993A (de)
CA (1) CA2140428C (de)
DE (2) DE69333344T2 (de)
WO (1) WO1994002501A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
ATE177430T1 (de) * 1993-05-12 1999-03-15 Novartis Erfind Verwalt Gmbh Nukleoside und oligonukleotide mit 2'- ethergruppen
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
AT407639B (de) * 1993-12-13 2001-05-25 Christian Dr Noe Modifizierte oligonukleotide, verfahren zu ihrer herstellung und verwendung als wirkstoffe zur herstellung von arzneimitteln
US5756707A (en) * 1994-12-13 1998-05-26 Perseptive Biosystems, Inc. Method of making 2'-O-alkyl pyrimidine ribonucleosides
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
NZ331217A (en) 1996-02-14 2000-02-28 Novartis Ag Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
CA2256765A1 (en) * 1996-06-06 1997-12-11 Novartis Ag 2'-substituted nucleosides and oligonucleotide derivatives
JP2000514307A (ja) * 1996-07-16 2000-10-31 ジェン―プローブ・インコーポレーテッド 増加した標的特異的ｔ▲下ｍ▼を持つ修飾オリゴヌクレオチドを用いた核酸配列の検出および増幅のための方法
US7070925B1 (en) 1996-07-16 2006-07-04 Gen-Probe Incorporated Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
US6025133A (en) * 1996-12-30 2000-02-15 Gen-Probe Incorporated Promoter-sequestered oligonucleoside and method of use
US6576752B1 (en) * 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
US6127533A (en) * 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
DE19741715A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6673912B1 (en) 1998-08-07 2004-01-06 Isis Pharmaceuticals, Inc. 2′-O-aminoethyloxyethyl-modified oligonucleotides
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US6403779B1 (en) 1999-01-08 2002-06-11 Isis Pharmaceuticals, Inc. Regioselective synthesis of 2′-O-modified nucleosides
WO2001002608A1 (en) * 1999-07-06 2001-01-11 Isis Pharmaceuticals, Inc. Oligonucleotides incorporating both 2-aminoadenine and 5-substituted pyrimidines
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
JP3596669B2 (ja) * 2000-08-08 2004-12-02 ヤマサ醤油株式会社 ２’−ｏ−アルキルグアノシンの製造法
EP2221376B1 (de) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
US7229976B2 (en) 2002-09-26 2007-06-12 Isis Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
SI1569695T1 (sl) 2002-11-13 2013-08-30 Genzyme Corporation Protismiselna modulacija ekspresije apolipoproteina B
EP2336318B1 (de) 2002-11-13 2013-04-24 Genzyme Corporation Antisense-modulation von apolipoprotein-b-expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
JP2009531283A (ja) 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
DE102006017600A1 (de) * 2006-02-09 2007-08-16 Friedel, Ruthard, Dr. Nucleosidanaloga als Genexpressionsregulatoren bei Viren
EP1820804A1 (de) * 2006-02-20 2007-08-22 Humboldt-Universität zu Berlin Lipophile Oligonukleotide
JP5070550B2 (ja) * 2006-04-13 2012-11-14 国立大学法人北海道大学 抗ヘルペスウイルス活性を有するヌクレオシド誘導体
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
CN108822174A (zh) * 2018-08-29 2018-11-16 上海兆维科技发展有限公司 新型核苷修饰物2’-eoe-鸟嘌呤核苷及其制备方法
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
IL293327B2 (en) * 2019-11-27 2026-04-01 Alnylam Pharmaceuticals Inc Synthesis of 3'-RNA oligonucleotides
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR927003044A (ko) 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
DE4037363A1 (de) 1990-04-09 1991-10-10 Europ Lab Molekularbiolog 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
DE4110085A1 (de) * 1991-03-27 1992-10-01 Boehringer Ingelheim Int 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
US5214135A (en) * 1991-08-30 1993-05-25 Chemgenes Corporation N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides

Also Published As

Publication number Publication date
EP0651759A1 (de) 1995-05-10
CA2140428C (en) 2003-07-08
EP0651759A4 (de) 1995-10-25
WO1994002501A1 (en) 1994-02-03
JP2000095793A (ja) 2000-04-04
JP3015464B2 (ja) 2000-03-06
DE69333842T2 (de) 2006-04-27
ATE256143T1 (de) 2003-12-15
EP0651759B1 (de) 2003-12-10
EP1223173B1 (de) 2005-07-13
EP1223173A3 (de) 2003-04-16
JPH1087689A (ja) 1998-04-07
AU4684993A (en) 1994-02-14
CA2140428A1 (en) 1994-02-03
DE69333842D1 (de) 2005-08-18
JPH07508042A (ja) 1995-09-07
EP1223173A2 (de) 2002-07-17
DE69333344D1 (de) 2004-01-22
DE69333344T2 (de) 2004-10-07

Similar Documents

Publication Publication Date Title
ATE299509T1 (de) Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
DE59100830D1 (de) Verfahren zur Herstellung von 3-Aminomethyl-3,5,5,-trimethyl-cyclohexylamin.
HUT62010A (en) Process for producing oligonucleotide analogs comprising terminal 3 - 3, or 5 - 5- intermolecular bonds
DE3889393D1 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidylaminen.
DE69131967D1 (de) Verfahren zur Herstellung von 1,1-Diarylprolinolen
EP0266168A3 (de) Zusammensetzungen und Verfahren zur Herstellung von Oligonukleotiden, deren 5' Ende phosphoryliert ist
DE3884644D1 (de) Verfahren zur Herstellung von 5'-Inosinsäure.
DE59003791D1 (de) Verfahren zur Herstellung von 1,3,3-Trimethyl-5-oxo-cyclohexan-carbonitril.
DE59105348D1 (de) Verfahren zur Herstellung von 1,4-Alkylendiaminen.
DE3789466D1 (de) 3,7-Disubstituierte-3-Cephemverbindungen und Verfahren zu ihrer Herstellung.
IL110968A0 (en) Nucleosides, nucleotides and oligonucleotides comprising tris-4,4',4"-tert-butylphenylmethyl, as protected group and their preparation
DE59303691D1 (de) Verfahren zur Herstellung von alpha-Chlor- 2,4,6-trimethylacetophenon
DE69300920D1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluorethan.
EP0521463A3 (en) Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
DE3887212D1 (de) Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin.
DE3874496D1 (de) Verfahren zur herstellung von 4,4'-dibrombiphenyl.
DE69206765D1 (de) Verfahren zur herstellung von 2',3'-dideoxy-beta-nucleosiden
DE3770059D1 (de) Verfahren zur herstellung von 4,4'-bis-phenol.
DE59106016D1 (de) Verfahren zur Herstellung von 2,3-Dihydrobenzofuranen.
ATE115139T1 (de) Verfahren zur herstellung von 2,4-diamino-6- piperidinyl-pyrimidin-3-n-oxid.
DE59007364D1 (de) Verfahren zur Herstellung von 2,4-Dihydroxybenzophenon.
DE3887293D1 (de) Si, Si'-Diorganyl-N-alkyl-tetrachlor-disilazane und Verfahren zu ihrer Herstellung.
DE69214982D1 (de) Verfahren zur Herstellung von 2',3'-dideoxy-2',3'-didehydronukleosiden
NO910607D0 (no) Fremgangsmaate for fremstilling av 3'-fluor-nukleosidanaloger.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties